Ludwig Kappos from University of Basel: Siponimod Shows Promise for Secondary Progressive Multiple Sclerosis

Video

As Ocrelizumab moves its way through the approval process for patients with primary progressive multiple sclerosis, data has been released on a trial for a potential treatment for the secondary progressive form.

As Ocrelizumab moves its way through the approval process for patients with primary progressive multiple sclerosis, data has been released on a trial for a potential treatment for the secondary progressive form.

Ludwig Kappos, MD, from the University of Basel discussed what could be a breakthrough treatment for siponimod at the annual ECTRIMS conference in London. Kappos said that while the medication is not a final step in the treatment of the condition, it is a solid first step to help patients that until now did not have a new treatment option on the horizon.

Related Videos
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
What Should the American Academy of Physician Associates Focus on in 2025?
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
© 2024 MJH Life Sciences

All rights reserved.